| 17.41 0.75 (4.5%) | 10-15 12:19 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 20.56 | 1-year : | 24.01 |
| Resists | First : | 17.6 | Second : | 20.56 |
| Pivot price | 15.54 |
|||
| Supports | First : | 15 | Second : | 13.39 |
| MAs | MA(5) : | 16.45 |
MA(20) : | 15.28 |
| MA(100) : | 14.88 |
MA(250) : | 26.97  |
|
| MACD | MACD : | 0.4 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 71.8 |
D(3) : | 66 |
| RSI | RSI(14): 60.7 |
|||
| 52-week | High : | 54.97 | Low : | 12.78 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ BHVN ] has closed below upper band by 2.2%. Bollinger Bands are 15.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 17.04 - 17.12 | 17.12 - 17.21 |
| Low: | 14.65 - 14.73 | 14.73 - 14.81 |
| Close: | 16.52 - 16.66 | 16.66 - 16.8 |
Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on development of therapies for neurological and immunoscience diseases that can change current treatment paradigms.
Tue, 07 Oct 2025
Should Biohaven's (BHVN) Accelerating Cash Burn and Shorter Runway Require Action From Investors? - simplywall.st
Tue, 07 Oct 2025
Should Biohaven's (BHVN) Accelerating Cash Burn and Shorter Runway Require Action From Investors? - Sahm
Tue, 07 Oct 2025
Biohaven Ltd. (BHVN) Stock Analysis: Exploring a Potential 198.62% Upside in Biotechnology - DirectorsTalk Interviews
Sun, 28 Sep 2025
Biohaven Ltd. (NYSE:BHVN) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Wed, 17 Sep 2025
Biohaven stock is a new Buy at Citi (BHVN:NYSE) - Seeking Alpha
Thu, 04 Sep 2025
Deadline Alert: Biohaven Ltd. (BHVN) Investors Who Lost - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 106 (M) |
| Shares Float | 88 (M) |
| Held by Insiders | 11.5 (%) |
| Held by Institutions | 82.7 (%) |
| Shares Short | 10,950 (K) |
| Shares Short P.Month | 10,650 (K) |
| EPS | -7.47 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.26 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -103.5 % |
| Return on Equity (ttm) | -296 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -8.78 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -645 (M) |
| Levered Free Cash Flow | -508 (M) |
| PE Ratio | -2.32 |
| PEG Ratio | 0 |
| Price to Book value | 13.62 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.84 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|